BidaskClub upgraded shares of Corcept Therapeutics (NASDAQ:CORT) from a hold rating to a buy rating in a research report sent to investors on Tuesday, BidAskClub reports.

Several other research analysts have also weighed in on CORT. Zacks Investment Research lowered Corcept Therapeutics from a hold rating to a sell rating and set a $14.00 price target on the stock. in a research report on Tuesday, February 4th. ValuEngine lowered Corcept Therapeutics from a sell rating to a strong sell rating in a research report on Tuesday, February 4th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $16.50.

NASDAQ:CORT traded up $0.04 during trading hours on Tuesday, hitting $13.27. 11,844 shares of the company’s stock traded hands, compared to its average volume of 778,442. The firm has a market cap of $1.51 billion, a P/E ratio of 18.58 and a beta of 1.25. Corcept Therapeutics has a twelve month low of $9.55 and a twelve month high of $17.48. The stock’s fifty day moving average price is $12.75 and its two-hundred day moving average price is $13.32.

Large investors have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new position in Corcept Therapeutics in the 4th quarter worth about $26,000. C M Bidwell & Associates Ltd. acquired a new position in Corcept Therapeutics in the 4th quarter worth about $45,000. LS Investment Advisors LLC increased its position in Corcept Therapeutics by 50.3% in the 4th quarter. LS Investment Advisors LLC now owns 7,802 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 2,610 shares during the last quarter. Trexquant Investment LP acquired a new position in Corcept Therapeutics in the 4th quarter worth about $140,000. Finally, Sterling Investment Advisors Ltd. increased its position in Corcept Therapeutics by 66.7% in the 3rd quarter. Sterling Investment Advisors Ltd. now owns 10,000 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 4,000 shares during the last quarter. 72.49% of the stock is currently owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.

Recommended Story: Rule of 72

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.